Last reviewed · How we verify
Pirfenidone Tablets
At a glance
| Generic name | Pirfenidone Tablets |
|---|---|
| Sponsor | Overseas Pharmaceuticals, Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1, Open-Label Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants (PHASE1)
- Fibrosis-Modulating Effects of Metformin and Pirfenidone in Oral Submucous Fibrosis (PHASE1, PHASE2)
- A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood (PHASE1)
- Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects (PHASE1)
- Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study (PHASE3)
- A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants (PHASE1)
- Safety and Tolerability of Pirfenidone in Acute Pancreatitis (PHASE1, PHASE2)
- Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pirfenidone Tablets CI brief — competitive landscape report
- Pirfenidone Tablets updates RSS · CI watch RSS
- Overseas Pharmaceuticals, Ltd. portfolio CI